Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) have been given an average recommendation of “Hold” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $10.60.
A number of equities research analysts have commented on GNMK shares. Zacks Investment Research raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. BTIG Research set a $11.00 price objective on GenMark Diagnostics and gave the company a “buy” rating in a research note on Tuesday, January 16th. BidaskClub raised GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of GenMark Diagnostics in a research note on Friday, January 19th. Finally, Canaccord Genuity reduced their price objective on GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, February 28th.
Shares of GenMark Diagnostics (GNMK) opened at $5.48 on Wednesday. The company has a quick ratio of 3.04, a current ratio of 3.44 and a debt-to-equity ratio of 0.29. GenMark Diagnostics has a one year low of $3.63 and a one year high of $13.67. The company has a market capitalization of $284.11, a P/E ratio of -4.53 and a beta of 0.99.
In related news, insider Hany Massarany sold 17,300 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $4.17, for a total transaction of $72,141.00. Following the transaction, the insider now owns 722,190 shares of the company’s stock, valued at $3,011,532.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Scott Mendel sold 6,275 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $4.17, for a total value of $26,166.75. Following the transaction, the chief financial officer now directly owns 246,161 shares in the company, valued at approximately $1,026,491.37. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,164 shares of company stock worth $217,957. 7.50% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its position in shares of GenMark Diagnostics by 4.1% during the second quarter. The Manufacturers Life Insurance Company now owns 36,023 shares of the medical equipment provider’s stock valued at $426,000 after buying an additional 1,410 shares during the last quarter. Voya Investment Management LLC lifted its holdings in GenMark Diagnostics by 17.5% during the second quarter. Voya Investment Management LLC now owns 19,725 shares of the medical equipment provider’s stock worth $233,000 after acquiring an additional 2,943 shares during the period. Teachers Advisors LLC lifted its holdings in GenMark Diagnostics by 11.3% during the fourth quarter. Teachers Advisors LLC now owns 125,245 shares of the medical equipment provider’s stock worth $522,000 after acquiring an additional 12,713 shares during the period. TD Asset Management Inc. lifted its holdings in GenMark Diagnostics by 13.8% during the third quarter. TD Asset Management Inc. now owns 130,280 shares of the medical equipment provider’s stock worth $1,255,000 after acquiring an additional 15,812 shares during the period. Finally, Wrapmanager Inc. lifted its holdings in GenMark Diagnostics by 121.3% during the fourth quarter. Wrapmanager Inc. now owns 39,547 shares of the medical equipment provider’s stock worth $165,000 after acquiring an additional 21,679 shares during the period.
COPYRIGHT VIOLATION WARNING: “GenMark Diagnostics, Inc (GNMK) Given Consensus Rating of “Hold” by Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/genmark-diagnostics-inc-gnmk-given-consensus-rating-of-hold-by-brokerages.html.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.